Compile Data Set for Download or QSAR
Report error Found 288 Enz. Inhib. hit(s) with Target = 'Solute carrier family 22 member 2'
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330053(US9663528, 63 | (2R,5S,13aR)-N-(2-chloro-4-fluorob...)
Affinity DataIC50: 42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50: 42nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335495((2R,5S,13aR)—N-(2-chloro-4-fluorobenzyl)-8-hy...)
Affinity DataIC50: 42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330054(US9663528, 64 | US9732092, Compound 64 | (2R,5S,13...)
Affinity DataIC50: 94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330054(US9663528, 64 | US9732092, Compound 64 | (2R,5S,13...)
Affinity DataIC50: 94nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330054(US9663528, 64 | US9732092, Compound 64 | (2R,5S,13...)
Affinity DataIC50: 94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50420232(CHEMBL2074900)
Affinity DataIC50: 100nMAssay Description:TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330049(US9663528, 45 | (13aS)-8-hydroxy-7,9-dioxo-N-(2,4,...)
Affinity DataIC50: 137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335491((13aS)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzy...)
Affinity DataIC50: 137nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM589177(US11548901, Compound 45)
Affinity DataIC50: 137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330045(US9663528, 39 | (2R,3S,5R,3aS)-N-(2,4-difluorobenz...)
Affinity DataIC50: 204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335488(US9732092, Compound 40 | US11548901, Compound 40)
Affinity DataIC50: 204nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335488(US9732092, Compound 40 | US11548901, Compound 40)
Affinity DataIC50: 204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330039(US9663528, 2 | US9732092, Compound 2 | (2R,5S,13aR...)
Affinity DataIC50: 240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330039(US9663528, 2 | US9732092, Compound 2 | (2R,5S,13aR...)
Affinity DataIC50: 240nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330039(US9663528, 2 | US9732092, Compound 2 | (2R,5S,13aR...)
Affinity DataIC50: 240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330040(US9663528, 3 | (2S,5R,13aS)-N-(2,4-difluorobenzyl)...)
Affinity DataIC50: 250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335482(US9732092, Compound 3)
Affinity DataIC50: 250nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330040(US9663528, 3 | (2S,5R,13aS)-N-(2,4-difluorobenzyl)...)
Affinity DataIC50: 250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330045(US9663528, 39 | (2R,3S,5R,3aS)-N-(2,4-difluorobenz...)
Affinity DataIC50: 358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335487(US9732092, Compound 39 | US11548901, Compound 39)
Affinity DataIC50: 358nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335487(US9732092, Compound 39 | US11548901, Compound 39)
Affinity DataIC50: 358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50170723(N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(im...)
Affinity DataIC50: 400nMAssay Description:Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330061(US9663528, 100 | (1R,4R,12aS)-N-(2,4-difluorobenzy...)
Affinity DataIC50: 450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335503((1R,4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-6,8-...)
Affinity DataIC50: 450nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM589189(US11548901, Compound 100)
Affinity DataIC50: 450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330052(US9663528, 55 | US9732092, Compound 55 | (1R,4S,12...)
Affinity DataIC50: 476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330052(US9663528, 55 | US9732092, Compound 55 | (1R,4S,12...)
Affinity DataIC50: 476nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330052(US9663528, 55 | US9732092, Compound 55 | (1R,4S,12...)
Affinity DataIC50: 476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330048(US9663528, 42 | (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N...)
Affinity DataIC50: 487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335490((2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50: 487nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330048(US9663528, 42 | (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N...)
Affinity DataIC50: 487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50010859(CHEMBL11 | Imipramin | IMIPRAMINE HYDROCHLORIDE | ...)
Affinity DataIC50: 600nMAssay Description:Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330043(US9663528, 13 | US9732092, Compound 13 | (2S,5R,13...)
Affinity DataIC50: 610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330043(US9663528, 13 | US9732092, Compound 13 | (2S,5R,13...)
Affinity DataIC50: 610nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330043(US9663528, 13 | US9732092, Compound 13 | (2S,5R,13...)
Affinity DataIC50: 610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM8961(CHEMBL95 | Cognex | cid_1935 | CHEMBL1337960 | 1,2...)
Affinity DataIC50: 680nMAssay Description:Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM85330(NSC_68647 | CAS_68647 | ONDANSETRON | Ondansetron ...)
Affinity DataIC50: 890nMAssay Description:Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50104435(4-(6-Guanidino-hexanoyloxy)-benzoic acid ethyl est...)
Affinity DataIC50: 900nMAssay Description:Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Rat)
University of Manitoba

Curated by ChEMBL
LigandPNGBDBM50420192(CHEMBL2074851)
Affinity DataIC50: 1.00E+3nMAssay Description:TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM39687(cid_5717105 | MLS000532635 | SMR000137574 | CHEMBL...)
Affinity DataIC50: 1.13E+3nMAssay Description:TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Rat)
University of Manitoba

Curated by ChEMBL
LigandPNGBDBM50420192(CHEMBL2074851)
Affinity DataIC50: 1.20E+3nMAssay Description:TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM45440(4-[5-(4-carbamimidoylphenoxy)pentoxy]benzenecarbox...)
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330058(US9663528, 96 | (1R,3R,11aS)-6-hydroxy-5,7-dioxo-N...)
Affinity DataIC50: 1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM335500((1R,3R,11aS)-6-hydroxy-5,7-dioxo-N-(2,4,6-trifluor...)
Affinity DataIC50: 1.36E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM589186(US11548901, Compound 96)
Affinity DataIC50: 1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM50241342(CHEMBL1502 | Protonix | SK-96022 | 6-(difluorometh...)
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330060(US9663528, 99 | US9732092, Compound 99 | (1R,3S,4R...)
Affinity DataIC50: 1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330060(US9663528, 99 | US9732092, Compound 99 | (1R,3S,4R...)
Affinity DataIC50: 1.51E+3nMAssay Description:Test compounds were serially diluted in DMSO and then spiked (2 μL) into in 0.4 mL KHB buffer containing wild-type or OCT2-transfected cells and...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSolute carrier family 22 member 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM330060(US9663528, 99 | US9732092, Compound 99 | (1R,3S,4R...)
Affinity DataIC50: 1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 288 total ) | Next | Last >>
Jump to: